viimane versioon :
22/08/2024
Infostab
ingredientide nimekiri
nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
uurimisrühmad
valistab
plakat
Sidemed
sponsorid
Autor
Kasutusjuhend
ajakiri
Cefepime dihydrochloride
keemiline struktuur
Kaubanduslikud nimed erinevates maades
Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist
Aspime
Venetsueela
Avipim
Türgi
Axépim
Prantsusmaa
Baxypime
Mehhiko
Cachepime
India
Cefalospim
Brasiilia
Cefemin
Kolumbia
Cefepem
Brasiilia
Cefepitax
Brasiilia
Cepim
Itaalia
Cepimex
Itaalia
Forcetex
Egiptus
Maxcef
Brasiilia
Maxipime
Ameerika ühendriigid, Austria, Belgia, Hispaania, Itaalia, Kanada, Kolumbia, Kreeka, Luksemburg, Maroko, Poola, Portugal, Rootsi, Saksamaa, Soome, Türgi, Ungari
Nebamix
Maroko
Olpelinol
Mehhiko
Pimcef
Maroko
Pimerzen
Mehhiko
Roxipime
Türgi
Unisef
Türgi
Vipefime
Mehhiko
Viited : Cefepime dihydrochloride
tüüp
avaldamine
182
ajaleht
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
251
ajaleht
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
873
ajaleht
Das Gupta V, Maswoswe J, Bailey RE.
Stability of cefepime hydrochloride dextrose in 5% dextrose injection and 0.9% sodium chloride injection.
Int J Pharm Compound 1997 ; 1: 435-436.
921
ajaleht
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1046
ajaleht
Stewart JT, Maddox FC, Warren FW.
Stability of cefepime hydrochloride in polypropylene syringes.
Am J Health-Syst Pharm 1999 ; 56: 1134.
1068
ajaleht
Stewart JT, Warren FW, Maddox FC.
Stability of cefepime hydrochloride in polypropylene syringes at -20°C, 4°C and 22-24°C.
Am J Health-Syst Pharm 1999 ; 56: 457-459.
1290
ajaleht
Williamson JC, Volles DF, Lynch PLM, Rogers PD, Haverstick DM.
Stability of cefepime in peritoneal dialysis solution.
Ann Pharmacotherapy 1999 ; 33: 906-909.
1410
ajaleht
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1605
ajaleht
Stewart JT, Maddox FC, Warren FW.
Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C.
Hosp Pharm 2000 ; 35: 1057-1064.
1625
ajaleht
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1626
ajaleht
Ling J, Das Gupta V.
Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Int J Pharm Compound 2001 ; 5: 151-152.
1648
ajaleht
Schlesser V, Hecq J-D, Vanbeckbergen D, Jamart J, Galanti LM.
Effect of freezing, long-term storage, and microwave thawing on the stability of cefepime in 5% dextrose infusion polyvinyl chloride bags.
Int J Pharm Compound 2002 ; 6: 391-394.
1673
ajaleht
Rabouan-Guyon M, Guet AF, Courtois PY, Barthes DMC.
Stability study of cefepime in different infusion solutions.
Int J Pharm 1997 ; 154: 185-190.
1712
ajaleht
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713
ajaleht
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721
ajaleht
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754
ajaleht
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1803
ajaleht
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1834
ajaleht
Trissel LA, Xu QA.
Stability of cefepime hydrochloride in autodose infusion system bags.
Ann Pharmacotherapy 2003 ; 37, 6: 804-807.
1945
ajaleht
Elwell RJ, Volino LR, Frye RF.
Stability of cefepime in icodextrin peritoneal dialysis solution.
Ann Pharmacotherapy 2004 ; 38: 2041-2044.
1982
ajaleht
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2042
ajaleht
Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM.
Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).
Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2046
ajaleht
Sprauten PF, Beringer PM, Louie ST, Synold TW, Gill MA.
Stability and antibacterial activity of cefepime during continuous infusion.
Antimicrob Agents Chemother 2003 ; 47: 1991-1994.
2134
ajaleht
Fubara JO, Notari RE.
Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions.
J Pharm Sci 1998 ; 87, 12: 1572-1576.
2141
ajaleht
Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2192
ajaleht
Cochran BG, Sowinski KM, Fausel C, Overholser BR.
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2231
ajaleht
de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247
ajaleht
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3254
ajaleht
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3385
ajaleht
Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3416
ajaleht
Csaba M, Boddu,S.H.S , Churchwell M.D.
Physical compatibility of sodium citrate with alcohol and cefepime.
Am J Health-Syst Pharm 2013 ; 70: 932-937
3520
Labor
Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3542
ajaleht
Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E.
Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion
Am J Health-Syst Pharm 2015 ; 72:390-395
3548
Labor
Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3549
Labor
Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3643
Labor
Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3674
Labor
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3827
plakat
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828
plakat
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829
plakat
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3879
ajaleht
Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948
ajaleht
Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
4055
ajaleht
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145
ajaleht
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254
ajaleht
D'Huart E, Vigneron J, Demoré B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4326
ajaleht
Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P.
Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion.
Pharmazie 2019 ; 74: 357-362.
4411
ajaleht
Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A.
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
Int J Pharm Compound 2020 ;24,3:238-241.
4434
ajaleht
Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4440
ajaleht
Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.
Ann Nutr Metab 2018 ; 73: 227-233.
4465
ajaleht
Foushee A, Meredith P, Fox Laura, Wilder A.
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4521
ajaleht
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020
4528
ajaleht
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4634
ajaleht
Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A.
Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
Antibiotics 2022 ;11,4: 458
4801
ajaleht
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:
Mentions Légales